Phytotherapy of cyclic mastalgia in patients with diffuse mastopathy and premenstrual syndrome
https://doi.org/10.21518/2079-701X-2019-6-136-140
Abstract
Research objective. To carry out the overview of the published works devoted to assessment of efficiency and safety of the phytodrug mastodynon, which includes Vitexagnus-castus extract, in treatment of mastalgia caused by a benign dysplasia of mammary glands and/or a premenstrual syndrome, with the analysis of use of the obtained data in clinical practice of obstetrician-gynecologist.
Materials and methods. The foreign and domestic articles which are selected in Pubmed, eLIBRARY according to keywords «cyclic mastalgia», «diffusion benign dysplasia of mammary glands», «premenstrual syndrome», «hyperprolactinemia», «Vitexagnus-castus», «mastodynon» are used. The results of the analysed clinical trials demonstrate efficiency of phytodrugs in treatment of mastalgia in patients with various forms of diffusion mastopathy and premenstrual syndrome.
Conclusion. Mastodynon can be recommended as effective and safe first-choice drug for treatment of a cyclic mastalgia in patients with a diffusion benign dysplasia of mammary glands and a premenstrual syndrome.
About the Author
N. V. Kulagina
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia Federation, Saint Petersburg
Russian Federation
Russian Federation
Kulagina Natalya Vladimirovna – Dr. of Sci. (Med.), Associate Professor, Professor of Chair for Obstetrics and Gynecology
191015, St. Petersburg, Kirochnaya St., 41
References
1. Carmichael A.R., Bashayan O., Nightingale P. Objective analyses of mastalgia in breast clinics: is breast pain questionnaire a useful tool in a busy breast clinic? Breast. 2006;15(4):498–50.
2. Genc V., Genc A., Ustuner E., Dusunceli E.B., Oztuna D., Bayar S., et al. Is there an association between mastalgia and fibromyalgia? Comparing prevalence and symptom severity. Breast. 2011;20(4):314–8.
3. Koçoğlu D., Kurşun S., Akin B.,1 Altuntug K. Mastalgia and associated factors: a cross-sectional study. Agri. 2017;29(3):100–108. DOI:.5505/agri.2017.91069.
4. Ader D.N., South-Paul J, Adera T, Deuster P.A. Cyclical mastalgia: prevalence and associated health behavioral factors. J Psychosom Obstet Gynaecol. 2001; 22:71–76.
5. Mansel R.E., Webster D.J.T., Sweetland H.M. Breast pain and nodularity. In: Mansel R.E., Webster D.J.T., Sweetland H.M. (eds) Benign disorders and disease of the breast. 3rd edn. Philadelphia: Saunders Elsevier; 2009.
6. Radzinsky V.E., Ordiyants I.M., Maslennikova M.N., Pavlova E.A. Mammary glands and gynecological diseases: from generality of pathogenetic possibilities to practical solutions. Opportunities for promoting health of women with uterine fibroids combined with benign dysplasias of the mammary glands. M.: Editorial office of StatusPraesens magazine, 2012. (In Russ).
7. Simonovskaya H.Yu., Ryzhova T.E. Phytopreparations in the treatment of benign and malignant diseases of the mammary glands. StatusPraesens. Ginekologiya, Akusherstvo, Besplodny Brak. 2017;4(40):89-97. (In Russ).
8. Maximov M.L. Treatment of mastopathy and mastalgia. Lechaschiy Vrach. 2014;2:25-27. (In Russ).
9. Ledina A.V., Prilepskaya V.N. Mastalgiya: clinical manifestations, diagnosis, treatment. Ginekologiya. 2011;13(5):66-69. (In Russ).
10. Yidirim A.C., Yildiz P., Yildiz M., Kahramanca S., Kargıcı H. Mastalgia-cancer relationship: a prospective stady. J. Breast. Health. 2015;11(2):88-91.
11. Kerchepaeva S. B., Smetnik A. A., Bespalov V. G. Mastopathy and breast cancer prevention as an interdisciplinary problem. RMJ. 2016;15:1018-1025. (In Russ).
12. Radzinsky V.E., Ordiyants I.M., Maslennikova M.N., Pavlova E.A., Kardanova V.V. Treatment options for uterine fibroids combined with benign breast dysplasias. Akusherstvo i Ginekologiya. 2013;44-47. (In Russ).
13. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2011;2:85-90.
14. Anderson E., Clarke R.B. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia. 2004;9:3-13.
15. Ezdakov Y.M., Gimaev IA, Tikhonov D.A. Review of modern concepts of the structure and function of estrogen receptors, their conformational changes, when interacting with agonists and antagonists. Universum: Khimiya i Biologiya: ehlektron. Nauchn. Zhurn. 2017;9(39). URL: http://7universum.com/ru/nature/archive/item/5083. (In Russ).
16. Rodionova M.V., Vorotnikov I.K., Rodionov V.V., Chkhikvadze N.V., Dudko E.A., Rjabchikov D.A., Oshkina E.V., Bogush T.A. Estrogen receptors beta as markers of the efficacy of hormone therapy for breast cancer. Rossiyskiy Bioterapevticheskiy Zhurnal. 2015;14(2):39-46 (In Russ).
17. Thijssen J.H.H. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas. 2004;49:25-33.
18. Pasqualini J.R. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003;46(1):45-54.
19. Ashrafyan L.A., Babaeva N.A., Antonova I.B., Ovchinnikova O.A., Aleshikova O.I., Motskobili T.A., Kuznetsov I.N. The level of estrogen metabolites balance in breast cancer and ways to correct it. Opukholi Zhenskoy Reproduktivnoy Sistemy. 2015;3:22-29. doi:10.17650/1994-4098-2015-11-3-22-29. (In Russ).
20. Gonzalez L., Zambrano A., Lazaro-Trueba I., Lopez E., Gonzalez J.J., Martin-Perez J., Aranda A. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene. 2009;28(10):1298–1308.
21. Podzolkova N.M., Sumyatina L.V., Mokhova Yu.A. Prolactin: the unknown about the known. Akusherstvo i Ginekologiya. 2015;12:46-50. (In Russ).
22. Lychkova A.E., Puzikov A.M. Prolactin and serotonin. Vestnik RAMN. Aktualnye Voprosy Fiziologii. 2014;1-2:38- 45. (In Russ).
23. Vuttke V., Zaydalova-Vuttke D., Jarri G., Artymuk N. The role of Vitex agnus castus in gynecological endocrinology. Ginekologiya. 2011;14(1):4-7.] (In Russ).
24. Radzinsky V.E., Ordiyants I.M. Premenstrual syndrome and benign dysplasia of the mammary glands - realities and prospects. Sovremennaya Meditsinskaya Nauka. 2011;1:5-19. (In Russ).
25. Tsoi L.K. Drug therapy for diffuse mastopathy and PMS. Effektivnaya Farmakoterapiya. Onkologiya, Gematologiya i Radiologiya. 2011;1:3-7. (In Russ).
26. Rozhkova N.I., Burdina I.I., Zapirova S.B., Mazo M.L., Prokopenko S.P., Jacobs O.E. Timely treatment of diffuse hyperplasia: prevention of breast cancer. Onkoginekologiya. 2016;1:4-11. (In Russ).
27. Artymuk N.V., Kondratieva T.A., Tachkova O.A. Principles of treatment of patients with infertility and insufficiency of the menstrual cycle luteal phase. Vopr. Gin., akush. i Perinatol. 2009;4(8):31-35. (In Russ).
28. Seidlova-Wuttke D., Wuttke W. The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots: effects of extracts of chasteberry (Vitex agnus castus) as a solution. Clinical Phytoscience. 2017; 3:6. doi: 10.1186/s40816-016-0038-z.
29. Powers C.N., Setzer W.N. A molecular docking study of phytochemical estrogen mimics from dietary herbal supplements. In Silico Pharmacol. 2015;3:4.
30. Webster D.E., He Y., Chen S.N., Pauli G.F., Farnsworth N.R., Wang Z.J. Opioidergic mechanisms underlying the actions of Vitex agnuscastus. L. Biochem pharmacol. 2011;81(1):170–7. doi: 10.1016/j.bcp.2010.09.013.
31. Elakad E.V., Sotnikova L.S., Tonkikh O.S. Hormonal regulation state in fibrocystic mastopathy. Mat i Ditya Na Kuzbasst. 2011;1:342-346. (In Russ).
32. Rafieian-Kopaei M., Movahedi M. Systematic Review of Premenstrual, Postmenstrual and Infertility Disorders of Vitex Agnus Castus. Electron Physician. 2017;9(1):3685–3689. doi: 10.19082/3685.
33. Cerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2017;20(6): 713-719. doi: 10.1007/s00737-017-0791-0.
34. Van Die M.D., Burger H.G., Teede H.J. Bone K.M. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trails. Planta Med. 2013;79(7):562-575.
35. Kulagina N.V. Treatment of mastalgia against the background of diffuse mastopathy in patients during the menopausal transition. Akusherstvo i Ginekologiya. 2016;11:135-141. (In Russ).
36. Kedrova A.G., Levakov S.A. Phytopreparations in the treatment of gynecological patients with severe mastalgia. Opukholi Zhenskoy Reproduktivnoy Sistemy. 2017;13(4):63-70. (In Russ).
37. Rozhkova N.I., Meskikh E.V. Use of Mastodynon in patients with different forms of mastopathy. Mammologiya/Ginekologiya. 2010;3:1–5. (In Russ).
38. Sotnikova L.S. et al. The hormonal regulation state in fibrocystic mastopathy. Mat i Ditya. 2011;1:342– 346. (In Russ)
Review
For citations:
Kulagina NV. Phytotherapy of cyclic mastalgia in patients with diffuse mastopathy and premenstrual syndrome. Meditsinskiy sovet = Medical Council. 2019;(6):136-140. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-136-140
Views:
878
Email this article 